CStone Pharmaceuticals CSPHF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $0.59
- Day Range
- $0.71–0.71
- 52-Week Range
- $0.59–1.01
- Bid/Ask
- $0.64 / $0.71
- Shares Outstanding
- 1.59B
- Market Cap
- $1.04B
- Volume/Avg
- 1,000 / 52,699
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 26.30
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
CStone Pharmaceuticals is engaged in developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment. The Group has been operating in one reportable segment, being the research and development of high-complex biopharmaceutical products, the sale of pharmaceutical products, and provide license of its IP or commercialisation licenses to customers.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 136
- Website
- https://www.cstonepharma.com
Valuation
|
Metric
|
CSPHF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 121.94 |
Price/Sales | 26.30 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CSPHF
|
|---|---|
Quick Ratio | 1.95 |
Current Ratio | 2.18 |
Interest Coverage | −31.72 |
Quick Ratio
CSPHF
Profitability
|
Metric
|
CSPHF
|
|---|---|
Return on Assets (Normalized) | −31.42% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −51.45% |
Return on Assets
CSPHF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|!BKy&L | LOCK|?>dwq | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|#zPj&z | LOCK|K@PMW | $79B | |||
| argenx SE ADR
ARGX
| LOCK|#M!!kN | LOCK|v< | $54B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|z%V?cg&Q | LOCK|r$VGH | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|w^#@&t | LOCK|Gv# | $39B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|h?MF!s | LOCK|?y$% | $31B | |||
| Incyte Corp
INCY
| LOCK|$?$<$@B | LOCK|V<@ | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|B%pnvy | LOCK|Msy | $23B | |||
| Moderna Inc
MRNA
| LOCK|&y$QZy | LOCK|BK | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|%!F!j? | LOCK|L?! | $17B |
United States